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1 Summary/ Abstract 
 
Cancer is a collection of related diseases characterized by an abnormal cell growth that 
tend to proliferate in an uncontrolled way in any part of the human body. There are 
many types of cancers but we will focus our study in Non-Hodgkin Lymphomas. The 
current cancer treatments include chemotherapy, radiotherapy and sometimes 
surgery. However, the greatest knowledge of cancer related genes has led to an 
improvement of targeted tumour therapies such as cancer immunotherapy or gene 
therapy. Cancer immunotherapy is based on understanding how to use the body’s 
adaptive immune system to destroy cancer. Cancer has the ability to evade the 
immune system by up regulating PD-L1. For this reason, PD-L1 is considered a 
potential target in cancer research. In the experimental part of the project, the aim 
was to validate the application in vitro of Polypurine Reverse Hoogsten Hairpins 
(PPRHs) for PD-L1 silencing in a cell line derived from a follicular lymphoma. PPPRHs 
are non-modified DNA molecules able to decrease gene expression, such as PDL-1 in 
our case.  
 
El càncer engloba un gran nombre de malalties que es caracteritzen pel 
desenvolupament de cèl·lules anormals, que es divideixen i creixen sense control a 
qualsevol part del cos. Existeixen molts tipus de càncers però en aquest treball ens 
centrarem en els Limfomes no Hodgkin. Avui en dia, el tractament d’aquesta malaltia 
inclou quimioteràpia, radioteràpia i de vegades cirurgia.  No obstant, l’ampli 
coneixement actual dels gens implicats en el càncer, ha permès desenvolupar noves 
teràpies dirigides com la immunoteràpia del càncer o teràpies gèniques per millorar el 
tractament d’aquesta. La immunoteràpia es basa en entendre com utilitzar el sistema 
immune del pacient per lluitar contra el càncer i destruir-lo. Les cèl·lules cancerígenes 
són capaces de sobre expressar una proteïna anomenada PD-L1 per tal d’evadir el 
sistema immunitari. És per això que PD-L1 es considera una potencial diana en la 
recerca de teràpies anticanceroses. L’altre meitat del treball es tracta d’una part  
experimental en la qual es pretén validar l’aplicació dels Polypurine Reverse Hoogsten 
Hairpins (PPRHs) pel silenciament de PD-L1 in vitro en una línia cel·lular provinent d’un 
Cancer immunotherapy and application of PPRHs for PD-L1 silencing in lymphomas Marta Bigordà Piella 
 4 
limfoma fol·licular. Els PPRHs són molècules de DNA no modificat capaces de disminuir 
l’expressió d’un gen, en aquest cas PD-L1. 
 
2 Initial discussion 
 
Cancer is a group of diseases characterized by an abnormal cell growth that tend to 
proliferate in an uncontrolled way in any part of the human body. Cancer spreads to 
nearby tissues and organs through a process of invasion. It can also invade blood and 
lymphatic vessels, and travel to other organs or tissues where it can be implemented. 
This process is called metastasis. This project will be focused in Non-Hodgkin 
lymphoma. Lymphoma is a cancer that begins in cells of the lymphatic system and it 
can involve other lymphoid organs such as the lymph, lymph vessels, lymph nodes, 
spleen, tonsils, thymus and bone marrow. 
 
Current cancer therapies count on surgery, systemic treatments such as chemotherapy 
or radiotherapy, and biological therapies with monoclonal antibodies or gene 
therapies directed to a specific gene. The present knowledge of tumour’s molecular 
biology is making it possible to develop new-targeted treatments such as 
immunotherapy or gene therapy. The first one marks an entirely different way of 
treating cancer, by targeting the immune system and not the tumour itself. Its aim is to 
enhance and stimulate the patient’s immune system to attack and destroy the tumour. 
Immunotherapy is becoming a powerful tool to fight cancer either alone or in 
combination with other therapies. In the same way, gene therapy is becoming really 
important for the treatment of a wide range of illnesses. Its aim is to create a 
treatment adapted to the genetic profile of the patient. In oncology, it basically 
consists on targeting a protein which is responsible for tumour cells proliferation and 
survival.   
 
In the present study a protein called programmed-death-ligand 1(PD-L1) which is 
broadly expressed in multiple cancers cells and tumour infiltrating cells was selected as 
the target. PD-L1 protects tumours from cytotoxic T cells by inhibiting the antitumor 
immune response. Therefore it enables cancers to evade the immune system. 
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2.1 Subjects integration 
 
Three subjects are included in this project: Molecular Biology, Immunology and 
Pharmacology. Molecular biology was useful to understand the molecular causes of 
cancer, the blockade of signalling pathways, basically the PD-L1/PD-1 pathway, and the 
role of PPRHs in gene silencing. Secondly, Immunology was basic to figure out the 
cancer immunity cycle and the way immunotherapy was able to enhance the immune 
system in order to attack and destroy cancer cells. Finally, Pharmacology is also 
involved since we were evaluating the current therapies for cancer treatment such as 
chemotherapy, radiotherapy and directed therapies with monoclonal antibodies.  
 
2.2  Contextualisation 
 
The self-therapeutic use of the immune system resources has always been a challenge 
for oncology researchers. Nevertheless, until now, anticancer treatments weren’t 
powerful enough to generate an important stimulus of the immune system. 
Fortunately, nowadays a new drug generation is available and capable of changing the 
treatment perspective. Currently anticancer immunotherapy is one of the main goals 
for worldwide researchers especially since when the prestigious magazine “Science” in 
2013 has chosen cancer immunotherapy as Breakthrough of the Year for 2013 (1). 
 
The origin of cancer’s immunotherapy started at late 1800s when William Coley, a 
famous American surgeon, observed that a bacterial infection generated spontaneous 
tumour regression. Coley took advantage of this natural phenomenon, developing a 
killed bacterial vaccine, “toxin Coley”, for cancer patients. Unfortunately, this therapy 
was not well accepted by medical institutions given that the toxin induced extremely 
high fevers. Clearly, Coley’s approach has a place in the past, present and future. It 
offered an opportunity for the development of a broadly applicable therapy for cancer 
(2).  
 
A century later, anticancer antibodies such as rituximab succeeded and created great 
interest in anti-body based therapies for lymphomas, leukaemia and solid tumours. 
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Currently, monoclonal antibodies are standard therapeutics for several cancers such as 
the anti-CD20 antibody, Rituximab, for B cell non-Hodgkin lymphoma (NHL). However, 
antibodies are not curative alone and they must be combined with cytotoxic 
chemotherapy for clinical benefit. This treatment combination really improves the 
cancer treatment in comparison to chemotherapy regimens alone (3).  
 
There has been an important progress in cancer research during 2014. This progress is 
directed towards a better understanding of cancer molecular biology (4). The greatest 
knowledge of cancer related genes and cancer molecular pathways led to an 
improvement of the targeted tumour and immune system therapies. This project will 
be focused in PD-L1, a target for immunotherapy with monoclonal antibodies and a 
target for gene silencing. PD-L1 is an overexpressed protein in a lot of cancers that 
enables cancer to evade the host immunity system.  
 
2.3 Objectives 
 
 
The main goal of this project is to make a bibliographical research about the current 
situation of immunotherapy, especially the use of monoclonal antibodies and gene 
therapies, for cancer treatment. Nowadays, PD-L1 is a potential target under 
investigation for cancer immunotherapy treatments. 
 
The second goal is to evaluate the possibility of using PD-L1 for targeted therapies in 
lymphomas. PD-L1 is an inhibitory ligand overexpressed in lots of cancers that enables 
cancer to evade the immune system. Silencing this protein with Polypurine Reverse 
Hoogsteen Hairpin (PPRHs) could be a way of decreasing PD-L1 expression in cancer 
cells to reduce this suppressing signalling. If PD-L1 silencing is effective, cancer cells 
could be well detected and destroyed by the immune system.  
 
The last aim of this project is to discuss whether the PPRH technology could be an 
appropriate treatment option for lymphomas in combination to chemotherapy 
regimens.  
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3 Introduction 
3.1 Cancer and lymphomas 
 
Cancer is a leading cause of disease worldwide. An estimated 14.1 million new cancer 
cases occurred in 2012 and it is also the leading cause of death worldwide, with 8.2 
million deaths in 2012 (5). Nowadays almost half of cancers occur in countries with a 
medium or low level of Human Development Index. The development in these 
countries will result in a reduction of infection related cancers, outweighed by an 
increase of cancers associated with reproductive, dietary and hormonal risk factors. 
This will represent an increase of 68% compared to 2012.(5)  
 
Cancer is a collection of related diseases that can start almost anywhere in the human 
body. They are an abnormal growth of cells that tend to proliferate in an uncontrolled 
way. Cancerous tumours can be malignant or benign. The malignant ones tend to 
invade other tissues and to metastasize, because cancer cells have different 
mechanisms that enable them to grow up and become invasive. After years of 
research, scientists have defined the different biological principles operating in a 
tumour cell. Cancer cells are able to evade cell death, immune destruction and growth 
suppressors to survive. They are also able to reprogram energy metabolism, to induce 
angiogenesis, to sustain proliferative signalling and above all to create genome 
instability and mutations. Thanks to these features we can distinguish a tumour cell 
from its non-malignant counterpart. Therefore, cancer research is focused on 
exploring innovative ways to target the biological mechanism of cancer. 
 
There are many different types of cancer and they are usually named after the organs 
or tissues where they originate. We will focus all our study on the most common blood 
cancer: Lymphoma.  
 
Lymphoma is a cancer that begins in cells of the lymph system. It occurs when cells of 
the immune system called lymphocytes grow and multiply uncontrollably. These 
cancerous lymphocytes can travel to many parts of the body, including the lymph 
nodes, spleen, bone marrow, blood, or other organs and form a tumour.  The two 
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main forms of lymphoma are Hodgkin lymphoma and non-Hodgkin lymphoma (NHL). 
Hodgkin lymphoma occurs when there are abnormal B-lymphocytes called Reed-
Sternberg cells; this type can usually be cured. However, NHL is a heterogeneous group 
of lymphoproliferative malignancies with different behaviour and responses to 
treatment. These diseases have been classified as B-cell and T-cell neoplasms based on 
the World Health Organisation (Annex 1). B-cell lymphomas represent 90% of all 
lymphomas and the most common types are diffuse large B-cell lymphoma (DLBCL), 
which is a usually aggressive and follicular lymphoma, which is usually indolent. (6) Our 
study will mainly be focused on Follicular Lymphoma since the cell lines used in this 
work are derived from this type of lymphoma. In Spain, NHL is the seventh leading 
tumour in both men and women and there are 3100 new cases for men and 2400 for 
women every year (7). 
 
Non Hodgkin Lymphoma can cause many different signs and symptoms depending on 
the type, the speed of growing, the body location and the age of the patient. In more 
than two from three patients, non-Hodgkin lymphoma is presented as an enlarged 
palpable lymph node. 40% of NHL patients present general symptoms such as fever, 
weight loss and night sweats. These symptoms are called “B symptoms” and they are 
more common in rapidly growing lymphomas. B symptoms are really useful for the 
diagnosis and for determining the stage and prognosis of the lymphoma. NHL can also 
cause anaemia, cough, chest pain and fatigue. However, in some cases NHL might not 
cause any symptoms until it grows quite large (7).  
 
The treatment and the chance of cure depend on the stage and the type of lymphoma. 
The treatment usually includes surgery, chemotherapy, radiotherapy, and sometimes 
stem cell transplant. The standard chemotherapy treatment for lymphomas is called 
CHOP and it consists of cyclophosphamide (an alkylating agent), 
hydroxydaunorubicin/doxorubicin (an intercalating agent), oncovin/vincristine (to 
prevent cell duplication) and prednisolone (corticosteroids). This regimen can also be 
combined with the monoclonal antibody rituximab (R-CHOP) directed against the 
protein CD20 found in pre-lymphocytes B and mature lymphocytes B. R-CHOP is 
generally given in 21-day intervals during 3 or 6 cycles in standard doses.   
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Therefore, the treatment for indolent Non-Hodgkin Lymphoma in early stage disease 
(Stage I and II) is based on radiation therapy and/or CHOP chemotherapy. For stage III 
and IV cases the treatment includes radiotherapy, chemotherapy with R-CHOP and/or 
radio immunotherapy. For aggressive Non-Hodgkin Lymphoma the treatment for early 
stages consists on R-CHOP chemotherapy for 3 or 6 cycles and radiotherapy. And in III 
and IV stages the treatment may include a monoclonal antibody therapy in 
combination with chemotherapy (R-CHOP) during 6 cycles (8). 
 
New types of treatments are being tested in clinical trials, such as vaccine therapies, 
gene therapy or new therapies with monoclonal antibodies like cancer immunotherapy 
with anti-PD-L1. For some patients, taking part in a clinical trial may be the best 
treatment choice. Clinical trials are part of the research process and they are really 
useful to improve the way cancer will be treated in the future.  
 
3.2  Cancer immunotherapy  
 
Immunotherapy is a cancer treatment different from other available therapies because 
it is not directed to destroy cancer cells. Its aim is to enhance and stimulate the 
patient’s immune system to attack and destroy the tumour. So, it is based on 
understanding how to use the body’s adaptive immune defence against cancer’s ability 
to evolve and evade destruction. This treatment will initiate or reinitiate a self-
sustaining cycle of cancer immunity (Figure 1), enabling it to amplify and propagate, 
but not so much as to generate unrestrained autoimmune inflammatory responses (9). 
This type of therapy is very specific for tumour cells and less harmful for healthy 
tissues. Once the immune system is enhanced, it has the potential to be self-
propagating. However, it may require quite a bit of time due to the fact that the 
immune system needs to get ready to fight against the tumour. 
 
a) Cancer immunity cycle 
 
It is important to understand the cancer immunity cycle before envisaging cancer 
immunotherapy (Figure 1). The cancer immunity cycle is the natural process by which 
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our immune system protects the body against cancer. Oncogenesis leads to the 
expression of antigens that can be captured by dendritic cells. Once captured, 
dendritic cells present antigens to T-cells in order to prime and activate cytotoxic T-
cells. Activated T-cells infiltrate the tumour microenvironment to recognise and kill 
cancer cells. Dying cancer cells release additional cancer antigens, propagating the 
cycle. Immune surveillance is an essential cellular process that prevents tumour 
formation in the human body. However, there are some cancer cells not effectively 
detected and not destroyed by T-cells. These cells continue to divide and grow (10).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1: The Cancer-Immunity Cycle. (9) 
 
This cycle can be divided into seven major steps. Each step of the cycle requires the 
coordination of stimulatory and inhibitory factors. Stimulatory factors promote 
immunity whereas inhibitors reduce immune activity. By disrupting the processes of 
this cycle, tumours can avoid detection of the immune system and limit the extent of 
immune destruction. One way of doing so is through the up regulation of inhibitory 
molecules such as programmed death ligand (PD-L1) in tumour cells and tumour-
infiltrating immune cells, like macrophages and dendritic cells (11).  
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b) Different types of immunological treatments for cancer 
 
There are lots of immunological treatment types and they can be classified into two 
major groups, non-specific immunotherapies and specific immunotherapies. The 
specific ones, basically vaccines and adoptive cell therapy, are directed towards a 
specific antigen or cell. Meanwhile, non-specific immunotherapy looks for a 
stimulation of the whole immune system. In this group we can include cytokines and 
immune control proteins. Moreover, monoclonal antibodies are designed to recognize 
tumour cells and create a passive immune response (12).  
 
- Monoclonal antibodies: are specific antibodies that target a tumour receptor 
expressed on cancer cells in order to modulate the tumour proliferation. They 
are periodically administered intravenously and sometimes attached to a toxin 
to enhance their effect. Some of these drugs are: Rituximab, Avastin, 
Herceptin, Erbitux… 
- Vaccines: there are two types of vaccines preventives and therapeutics. The 
first type is used to prevent the development of the tumour such as 
papillomavirus and hepatitis B vaccine. Therapeutics vaccines are made from a 
patient’s own tumour cells with the goal of strengthening the body’s immune 
system against cancer. The only one accepted in USA is the sipuleucel-T vaccine 
for metastatic prostate cancer. 
- Adoptive cell therapy: lymphocytes cells are extracted from the patient, 
cultivated, reproduced and re-infused to the patient. Nowadays this type of 
treatment is only under experimental observation. However, a similar approach 
called CAR (chimeric antigen receptors) is becoming really successful in 
refractory leukaemia treatment. 
- Cytokines: two types of cytokines are used to treat patients with cancer 
interleukins and interferon. They are broadly used to generate a non-specific 
stimulation of the immune system. Nowadays recent advances are enabling the 
development of more effective immunotherapies with cytokines or in 
combination of these agents. 
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- Immune control proteins: they have the ability to block certain proteins, called 
immune checkpoints proteins that limit the strength and duration of the 
immune responses. The blockade of these proteins increases the ability of the 
patient’s immune system to detect and destroy cancer cells. Some of these are 
Ipilinumab and anti PD-L1/PD1 drugs basically used in melanoma and lung 
cancer (12)(13). 
 
c) PD-L1 pathway 
 
Under normal conditions, the PD-L1 pathway (Figure 2) can play an important role in 
maintaining immune homeostasis and protecting normal cells from autoimmunity (14). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2. Tumour immunology and the PD-L1/PD-1 pathway (15) 
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However, cancer uses the PD-L1 pathway to inhibit cytotoxic T-cell activity in the 
tumour microenvironment and to inhibit cancer immunity cycle propagation in the 
lymph nodes. PD-L1 is found in the surface of cancer cells and in tumour infiltrating 
immune cells such as T and B cells, dendritic cells and macrophages. PD-L1 binds to PD-
1 and B7.1 receptors leading to the deactivation of cytotoxic T-cells. PD-1 is an 
inhibitory receptor expressed on the surface of T cells that works as an immune 
checkpoint. This binding releases an inhibitory signal that reduces the production of 
cytokines and the proliferation of T cells. Cancer uses PD-L1 up-regulation to evade the 
host immune response during progression of the disease. (15)  
 
Preventing PD-L1 from binding to its receptors on T cells (B7.1 and PD-1) may allow T-
cells to remain active (15)(16). In these conditions, T-cells may be able to respond and 
kill cancer cells. Thus, the aim of cancer immunotherapy is to block the PD-L1/PD-1 and 
PD-L1/B7.1 pathways to let the body better detect and fight cancer. 
  
 
 
 
 
 
 
 
 
 
 
Image 1. PD-L1 binds to B7.1 and PD-1 on cytotoxic T cells and disables their  
anticancer immune response (17) 
 
d) PD-L1 expression 
 
Researchers are investigating whether high amounts of PD-L1 may indicate a better 
response to immunotherapies that interfere with PD-L1. Measuring the amount of 
PD-L1 on both tumour cells and tumour-infiltrating cells may help to predict the 
effect of certain medicines. This could contribute to determine which people are 
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more likely to respond to cancer immunotherapy alone or in combination with 
other cancer therapies (15). Overexpression of PD-L1 has been observed in 
multiple cancer types, making PD-L1 a potential target and a potential biomarker in 
cancer research.   
 
Cancer Type % PD-L1 expression 
Melanoma 40-100 
Non- small cell lung cancer 35-95 
Nasopharyngeal cancer 68-100 
Glioblastoma/mixed glioma 100 
Colon adenocarcinoma 53 
Hepatocellular carcinoma 45-93 
Urothelial cancer 28-100 
Multiple myeloma 93 
Ovarian cancer 33-80 
Gastric carcinoma 42 
Esophageal cancer 42 
Pancreatic cancer 39 
Renal cell carcinoma 15-24 
Breast cancer 31-34 
Lymphomas 17-94 
Leukemias 11-42 
 
Table 1: Expression of PD-L1 by tumour type according to Chen DS, a current review of PD-L1 expression (15) 
 
Tumour expression of PD-L1 has been reported to be associated with positive 
responses to PD-L1/PD-1 pathway inhibition in clinical studies (15). As shown in Table 
1, PD-L1 is highly expressed in many human cancer types. However, in lymphomas, PD-
L1 expression varies from 17% to 94% because peripheral T-cell lymphomas, diffuse 
large cell lymphomas and small lymphocytic lymphoma are included in this category.  
In consequence targeting PD-L1/PD-1 pathway in lymphoma patients could lead to 
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different responses. PD-L1 expression should be measured before deciding whether 
immunotherapy is the appropriate treatment. 
 
e) Anti PD-L1 drugs 
 
Nowadays, there are research cancer immunotherapy studies with monoclonal 
antibodies designed to interfere with PD-L1 and PD-1.  Antibodies against PD-1 inhibit 
this receptor from binding to PD-L1 and PD-L2 so they could be appropriate for 
tumours with a high expression of both ligands. But the direct inhibition of PD-L1 can 
lead to serious autoimmune adverse events (18). Otherwise, anti-PD-L1 molecules are 
designed to prevent PD-L1 from binding to PD-1 and B7.1 on the surface of T cells 
allowing cytotoxic T cells to kill cancer cells expressing PD-L1. In this direction, 
Atezolizumab (MPDL3280A) from Genentech, is an anti-PD-L1 for solid tumours under 
clinical trial evaluation. In Table 2 some anti PD-L1 and PD-1 currently being developed 
in oncology are shown.  
 
Therapeutic Blockade Company Antibody Type Development 
MPDL3280A Anti PD-L1 Genentech IgG1 Phase II 
MEDI-4736 Anti PD-L1 AstraZeneca IgG1 Phase I 
Nivolumab Anti PD-1 Bristol-Myers  IgG4 Phase III 
Lambrolizumab Anti PD-1 Merck & Co IgG4 Phase III 
Pidilizumab Anti PD-1 Cure Tech IgG4 Phase II 
AMP 224 Anti PD-1 GSK IgG4 Phase I 
 
Table 2: Inhibitors of PD-L1 or PD-1 currently being developed in Oncology (9) 
 
Other new therapies are focused on targeting overexpressed cancer proteins such as 
BCL-2 or p53 that are required for cancer cell survival. These therapies are highly active 
but they are incapable of changing with cancer’s ability to mutate and evolve. 
Nevertheless, anti PD-L1/PD-1 agents are able to enhance the host immune response 
to generate durable and adaptable antitumor immunity. Once immune response is 
enhanced, it has the potential to be self-propagating. PD-L1/PD-1 targeted therapy 
may not be enough to treat the majority of cancers. Combination approaches may 
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probably be the best treatment choice to induce cancer durable regression. These 
combined therapies could include radiation therapy or chemotherapy, antiangiogenic 
therapy and tumour-targeted therapies. The combination of PD-L1/PD-1 with other 
targeted therapies will also improve cancer treatment responses. (15) 
 
Immunotherapy with anti PD-L1/PD-1 molecules would help patients to better fight 
this highly aggressive evolving disease.  
 
3.3 Gene therapy 
  
Gene therapy is a treatment that involves the transfer of genetic material into the 
patient’s cells in order to cure a disease or to improve the clinical status of the patient 
(19). Gene therapy may be a promising treatment option for a wide range of diseases 
including cancer, cystic fibrosis, heart disease, diabetes and haemophilia (20). 
The development of this type of therapies requires a long process that starts with the 
determination of the molecular defect and the mutated gene or genes that are causing 
the disease. Once the therapeutic gene is identified, a functional copy that corrects the 
problem will replace it. It works by introducing DNA with a healthy copy of the 
defective gene into the patient cell.  
In cancer, it is difficult to find the appropriate genomic change since it is a polygenic 
disease caused by a huge variety of gene alterations. These alterations can be 
functional or structural including mutations, insertions, deletions, amplifications, 
fusions and translocations.  
 
 
 
 
 
 
 
 
 
Figure 3: introduction of DNA with the corrected gene (21) 
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Cancer gene therapy nowadays is based in the following strategies: 
- To replace the mutated genes. Some cells have genes that gain or lose their 
function. Replacing the altered or mutated genes could be helpful to treat 
some diseases. For example, many cancers have mutated versions of the p53 
protein, a proto-oncogene that interferes with the apoptosis process. The 
introduction of a normal p53 gene could make cancer cells more sensitive to 
standard chemotherapy than cancer cells with the altered protein.  
- To silence or “knock out” a mutated gene. Activated, overexpressed or mutated 
genes that cause the disease can be silenced to avoid tumour growth and 
tumour proliferation. Otherwise, we can stimulate the expression of genes that 
help prevent the disease. 
- To make the immune system more sensitive to disease cells.  Gene therapy 
could be used to train the immune system to recognise disease cells by 
promoting cytokines or by stimulating tumour immunity cycle.  
- Other strategies such as blocking oncogenes (genes that promote tumour 
formation) or stimulating tumour supressing genes.  
 
There are two different types of gene therapy depending on which types of cells are 
treated, either germline or somatic. In germline gene therapy DNA is transferred to 
reproductive cells (cells responsible of producing eggs or sperm). Therefore, the effects 
of the therapy will be transferred to the following generation. Germinal gene therapy 
it is currently not legal. 
Somatic gene therapy targets all the cells of the body except the germinal ones. This 
means that the effects of this gene therapy will not be inherited. It can be done in vivo 
or ex vivo. The ex vivo strategy consists on removing the cells from the body to 
transfect them while in vivo gene therapy consists on doing the genetic modification 
inside the patient’s body.  
 
A key factor for gene therapy is the development of a delivery system capable of 
transferring the gene to the patient’s cells. The vector that delivers the DNA is usually 
a virus (retrovirus, adenovirus or virus associated to adenovirus) or a liposome. Naked 
DNA transfer is also viable for gene delivery. The type of delivery vehicle depends on 
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the specificity of the transfection, the size of the gene and the target cells. Once the 
altered genes are carried inside the cells of the patient they will be integrated into the 
genome of the patient and they will ideally produce the therapeutic protein (20). 
    
 
 
 
 
 
 
 
 
      
 
 
                        Figure 4: gene transfection with viral vector (22) 
 
Gene therapy allows for an incredible diversity of cancer treatment options. It can be 
used to complement and increase the effectiveness of current chemotherapeutic 
regimens as well as to develop personalized cancer therapies. With the current 
information of the molecular causes of cancer and the knowledge of the implied 
genes, gene therapy can be a huge opportunity for creating more sophisticated and 
personalized treatments for the patients.   
 
3.4  Silencing with PPRHs 
 
Gene silencing consists on decreasing the expression of a gene in order to treat a 
disease. Nowadays, molecules like antisense oligonucleotides (aODNs), small-
interference RNA (siRNA) or Triplex Forming Oligonucleotides are being used to silence 
gene expression in biomedical research.  However, they present some disadvantages 
such as instability and activation of the immune response (23). The research group 
that I’ve been working with has developed a new type of molecule capable of 
decreasing the gene expression. These molecules are Polypurine Reverse Hoogsteen 
Hairpins (PPRHs). PPRHs are nonmodified DNA molecules formed by two antiparallel 
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polypurine domains linked by a pentathymidine loop that allows the formation of 
intramolecular reverse Hoogsten bonds (23). These hairpins bind to polypirimidine 
targets in the DNA through Watson-Crick bonds and maintaining their original 
structure. PPRHs molecules can target both coding and template stretches. Coding-
PPRHs directed against the DNA coding strand can also interact with the mRNA 
because they have the same sequence and orientation. In this direction, coding-PPRHs 
can interfere with the splicing process leading to a decrease in mRNA levels (24). On 
the other hand, Template PPRHs are directed to the template strand of the DNA and 
have the ability to decrease mRNA levels by inhibiting gene transcription (25).   
Therefore, PPRHs are polypurine sequences that bind to polypirimidine sequences in 
the DNA to knock down gene expression. This property allows us to selectively 
modulate the activity of a specific gene, in this case PD-L1. 
 
For this project we have designed a PPRH against PD-L1 (programmed cell death 
ligand) in order to reduce its expression and make cancer more vulnerable to the 
patient’s immunity system. So, instead of using anti-PD-L1 monoclonal antibodies for 
cancer immunotherapy, we have used PPRHs against PD-L1 in the same direction.  
 
4 Objectives/ hypothesis of the experimental design  
 
I’ve developed this project under the supervision of Doctors Veronica Noé and Carles 
Ciudad, from the research group of Cancer Therapy in the Department of Biochemistry 
and Molecular Biology of the School of Pharmacy in the University of Barcelona.  
 
In this research project, our main goal was to evaluate the possibility of using PD-L1 as 
a target to treat Lymphomas or almost reduce their progression. PD-L1 is a trans 
membrane protein overexpressed in a lot of cancers, responsible of protecting 
tumours from cytotoxic T cells. We targeted PD-L1 with Polypurine Reverse-Hoogsten 
Hairpins (PPRHs) to silence the gene and induce lymphoma remission. Targeting PD-L1 
is probably not enough to kill all cancer cells, and for this reason we also wanted to 
evaluate the effect of combining gene therapy (PPRHs) with chemotherapy regimens. 
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A secondary goal was to demonstrate if the tumour expression of PD-L1 is associated 
to a better response to PPRHs treatment. 
 
5 Experimental design 
 
We designed this experiment with two main objectives: 
- To incubate the lymphoma cell line (WSU) used as a model with PPRHs against 
PD-L1 in order to validate their effects, to determine their cytotoxicity and to 
evaluate the effect of combined therapies (PPRHs + chemotherapy). 
- To determine the levels of PD-L1 expression in WSU cells 
 
PPRHs were incubated either naked or complexed with a cationic liposome, such as 
DOTAP or Viromer®Green, alone or in combination with Bendamustine. In all cases we 
analysed whether PPRHs had the ability to knock down the expression of PD-L1, by a 
decrease of the mRNA levels of PD-L1, using the MTT assay. A lower amount of mRNA 
meant the silencing process had been effective. We also tried to determine the 
cytotoxicity of PPRHs and its vehicles. 
 
In addition we determined PD-L1 levels in WSU cells using RT-Real Time PCR and 
comparing it to other cell lines with reported PD-L1 overexpression. In this direction, 
we have used PC3, a human prostate cancer cell line, and MiaPaca-2, a human 
pancreatic cancer cell line. PD-L1 expression could vary from 17% to 94% in 
Lymphomas.  
 
 
6 Materials and methods  
6.1 Design of PPRHs 
 
The PPRHs used in this study were formed by two antiparallel polypurine domains, 
bound by intramolecular reverse Hoogsten bonds, and linked by a pentathymidine 
loop (24). Triplex Forming Oligonucleotide Target Secuence Search Software was used 
to find polypirimidine sequences in the PD-L1 gene in order to design the 
corresponding PPRH against PD-L1 (26). A sequence of 28 bases with only three 
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pyrimidine interruptions was found in intron 1 of the gene located in chromosome 9 
(Annex II). This sequence was used for the design of the Wild Type Coding PD-L1 
hairpin.  
 
 
 
Figure 5: Coding-PPRHs binding to its target sequence in the PD-L1 gene. Curved lines represent Hoogsteen bonds 
and straight lines Watson-Crick bonds. The blue sequence corresponds to the polypirimidine ssDNA target in the 
gene. 
 
In Figure 4 we can see a schematic representation of the Wild type Coding-PPRH and 
its binding to its polypirimidine DNA target in intron 1 of the PD-L1 gene. As shown, 
the Coding-PPRH hairpin forms a triplex structure with the DNA that knocks down the 
expression of the PD-L1 gene.  
 
PPRHs were synthetized as non-modified oligodeoxynucleotides by Sigma-Aldrich. 
After that, they were dissolved in sterile RNase-free TE buffer and stored at -20ºC.  
 
6.2 Cell line (WSU) 
 
All the experiments were performed with a human B cell line called WSU-FSCCL (WSU), 
a generous gift from researchers at IDIBAPS, Hospital Clinic of Barcelona. It was 
established from a patient with low-grade follicular (small cleaved cell) lymphoma in 
leukemic phase. These cells presented two chromosomal translocations t(14;18) and 
t(8;11). The first translocation is common in follicular lymphoma while the second one 
is not usual in this type of lymphomas and it may probably confer the aggressive 
Template:	3’-ATTCTTCTACTAACAGTGGGGAGTGGGAAGGGGAGAGAGTTGGATTTGACT-5’	
5’-AACAGTGGGGAGTGGGAAGGGGAGAGAG	
HpPDL1I1-C/WT	
3’-AACAGTGGGGAGTGGGAAGGGGAGAGAG	
5T	
Coding:	5’-TAAGAAGATGATTGTCACCCCTCACCCTTCCCCTCTCTCAACCTAACTGA-3’	
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behaviour seen in the terminal phase of the disease. The t(8,11) translocation is a 
juxtaposition of the region of the BCL-2 gene leading to an overexpression of BCL-2 
another PPRH target possibility studied by my team mate. Nevertheless, this cell line 
does not present any anomaly towards PD-L1. WSU cells reacts with monoclonal 
antibodies to B-cell antigens.  
 
6.3 Cell culture 
 
WSU-FSCCL cells were grown in RPMI medium containing 10% growth factors (FCS), 
two antibiotics and a pH regulator to avoid the acidification of the medium. This 
medium has only one-month validity. While most cancer cells get attached to the 
plate, lymphoma cells live in suspension. This means that, it is necessary to centrifuge 
them before changing the culture. Lymphoma cells grow and multiply really easily 
however they are quite fragile and difficult to transfect.  
 
RPMI + 10% FCS for 500mL 
RPMI………………………………………………………………5,215g 
Streptomycin…………………………………………………..50mg 
Penicillin G………………………………………………………31,25 mg 
NaHCO3 …………………………………………..…….…………1g 
FCS…………………………………………………………………..50mL 
Sodium pyruvate……………………………………………..5mL solution 100mM 
HEPES…………………………………………………………….500μL solution 1M 
H2O…………………………………………………………………444,5mL 
 
6.4 PPRH transfection and liposomes 
 
PPRH transfection needs a delivery system capable of transferring the hairpin to the 
cells. As we said, the delivery system can be viral or non-viral including 
electroporation, cationic liposomes or microinjections.  Most of the delivery methods 
present problems with the DNA delivery and sometimes they present cytotoxicity 
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problems. Two cationic liposomes DOTAP (N-[1-(2,3-dioleoyloxy)propyl]-N,N,N-
trimethylammonium methylsulfate) and Viromer Green were chosen in order to 
reduce these problems. The transfection process is different depending on the vehicle.  
 
When DOTAP was used as a vehicle, PPRHs were first mixed with DOTAP for 20 
minutes. Then, cells were transfected and the plate was incubated for 3 to 7 days. 
However, in case of using Viromer®GREEN the transfection process was more complex. 
First, PPRHs were diluted with Buffer GREEN obtaining an 11μM dilution (Tube 1). In 
Tube 2, Buffer GREEN was added to Viromer®GREEN and vortexed for 3 to 5 seconds.  
After that, 1μL of Tube 1 was mixed swiftly with 9μL of Tube 2 and incubated for 15 
minutes at room temperature. 15 minutes later, the transfection complexes were 
added to the cells and incubated as usual.  
 
6.5 MTT assay 
 
The MTT (3-[4,5-dimethylthiazol-2-yl]-2,5 diphenyl tetrazolium bromide) assay was 
used to evaluate the effect of PPRHs in our cell line (WSU). MTT measures the cell 
proliferation rate or the reduction in cell viability by the determination of the total 
mitochondrial activity (27).  
 
MTT assays were performed in a 12, 24 or 96 well dishes. The assay always included 
blank wells with only medium, negative control wells with cells and medium, positive 
control wells with untreated cells and test cells treated with PPRHs. Treated cells were 
usually present in duplicate or triplicate. Once the assay was designed, we selected the 
optimal number of cells, usually between 10.000 and 40.000 cells per well. The optimal 
cell number was plated in 12 or 24 well dishes with 500μL of RPMI medium or in 96 
well dishes with 100μL of medium.  
 
After the incubation period, for both transfection vehicles, the MTT reagent was added 
to the culture medium and allowed to react 2h at 37ºC. Once a purple precipitate was 
visible, we started with the addition of the lysis solution (24V Isopropanol + 1V HCl 1M) 
and we pipet up & down. Cell viability was measured at 570nm in a 
Cancer immunotherapy and application of PPRHs for PD-L1 silencing in lymphomas Marta Bigordà Piella 
 24 
Spectrophotometer. Absorbance values that were lower than the untreated control 
cells (negative control) indicate a reduction in cell viability. While higher absorbance 
values indicate an increase in cell proliferation. Therefore, we wanted to see a 
decrease in the absorbance values to correlate it with an increase in cell death due to 
PPRH transfection.  
 
    
 
   
 
  
  
Figure 6: MTT assay example with DOTAP 
 
6.6 mRNA analyses, RT-PCR and Real Time PCR 
 
Real-time PCR is a simple method to determine the amount of a target sequence or 
gene present in a sample (28). Before performing a Real Time PCR reaction, it is 
needed to extract the RNA from the sample with Trizol and convert the RNA into cDNA 
by reverse transcription (RT). This method was used to quantify PD-L1 levels in the 
untreated and the treated WSU cells in order to predict the effects of PPRHs 
transfection and to evaluate the effect on gene silencing. 
 
For mRNA analyses, total RNA from 50.000 WSU cells was extracted using Trizol 
according to the lab PNT. The amount of RNA was determined by measuring its 
absorbance in a Nanodrop spectrophotometer. RNA quality was correct when the 
Ratio 260/280 (RNA/proteins) was close to 2 in the Nanodrop spectrophotometer. 
 
Once RNA was extracted, cDNA was synthetized with the reverse transcriptase 
mixture. This mixture contained 0,25μL of the random hexamers 125μg/μL dilution 
(primers), 1μL of the dNTPs 500μM dilution, 2μL of Buffer 10x, 20 units of RNAse 
inhibitor and 200 units of Moloney-Murine Leukemia Virus Reverse Transcriptase (M-
- Blank: Medium 
- Negative control: cells and medium 
- Positive control: cells, medium and DOTAP 
- Treated cells: cells, medium, DOTAP and PPRHs 
in different concentrations 
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MuLV). 4,75μL of the reaction mixture were added to 15,25μL of the RNA solution and 
incubated at 42º for 1h. 
 
3μL of the cDNA mixture were used for the real time PCR amplification. The reaction 
was performed using the ABI-Prism 7000 Sequence Detection System (Applied 
Biosystems). The final volume for the reaction was 20μL, 3μL of cDNA and 17μL of the 
PCR mixture. The PCR mixture contained 1xSYBR Universal PCR Mastermix, 0,25μM of 
reverse and forward primers and 6μL of H2O MQ. The mixture and the cDNA were 
placed in the PCR plate in order to start the Real Time-PCR. PCR cycling conditions 
were 10 minutes denaturation at 50ºC, 10-minute denaturation at 95ºC, followed by 
40 cycles of 15s at 95ºC and 1 min at 60ºC. The mRNA amount of PD-L1 was 
determined by the ΔΔCT method, where CT is the cycle in which the amplified product 
reaches the fluorescence threshold (25).  
 
  PC3            M2      WSU           Primers: 
   PD-L1 (I) 
 
  PD-L1 (II) 
 
  APRT 
 
 
The primers sequences for PD-L1 were:  
 Forward (I): 5’-ACAATTAGACCTGGCTGCAC-3’ 
 Reverse (I): 5’-GTATGGGGCATTGACTTTCAC-3’ 
 Forward (II): 5’-CATGACCTACTGGCATTTGCTG-3’ 
 Reverse (II): 5’ACATATAGGTCCTTGGGAACCG-3’ 
 
APRT mRNA was used as an endogenous control. 
 
Therefore, two pairs of PD-L1 primers were used to determine PD-L1 levels in WSU 
treated and untreated cells, in MiaPaca-2 and in PC-3 cell lines using the APRT gene as 
a control. It is known that MiaPaca-2  and PC-3  cell lines overexpress PD-L1.  
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7 Results and discussion 
7.1  Incubation with PPRHs against PD-L1  
 
a) Effects of PPRHs against PD-L1 using DOTAP as a vehicle 
 
WSU cells were incubated with HrpPD-L1-C WT for 6 days. After that period, cell 
viability was analysed with the MTT assay. A decrease in the absorbance of the 
transfected cells in relation to the control was observed (Figure 7). This could probably 
mean that WSU cells were being transfected and killed by the combination 
PPRH+DOTAP. Thus, when the higher hairpin concentration was used, the most 
reduction in cell viability was obtained.  
 
Figure 7: Cell viability of WSU cells incubated with PPRHs  
against PD-L1 (10nM and 100nM) using DOTAP as a vehicle. 
 
We repeated the experiment with 20.000 and 30.000 cells in 96 well dishes for 72h. 
The main aim of it was to see if the cells were being killed by HrpPD-L1. A control 
hairpin (HrpLac) was also included in the experiment. Theoretically, the control hairpin 
should not affect cell viability because its target gene is not present in cancer cells. 
 
Unfortunately, a decrease in cell viability could be observed with both PPRHs as shown 
in the following graphs (Figure 8 and 9). Consequently, we started to think that either 
the vehicle (DOTAP) or the hairpin were cytotoxic by themselves.  
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Figure 8: Cell viability of WSU cells incubated with PPRHs  
against PD-L1 (0nM, 50nM and 100nM) using DOTAP as a vehicle. 
Figure 9: Cell viability of WSU cells incubated with PPRHs  
against Lac (0nM, 10nM and 100nM) using DOTAP as a vehicle. 
 
b) PPRH and DOTAP cytotoxicity 
 
40.000 cells were incubated during 48 hours with increased concentrations of DOTAP, 
1/10 dilution of DOTAP and Hairpin PD-L1-C WT with DOTAP. After the MTT assay a 
similar tendency in cell death was observed in both treated and untreated cells (Figure 
10, 11 and 12). Therefore, we concluded that DOTAP was toxic for WSU cells. The 
effects observed in previous experiments were probably due to the toxicity of the 
vehicle and not to gene silencing. Consequently, another vehicle called Viromer Green 
was chosen to transfect the hairpin.    
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Figure 10: Cell viability of WSU cells treated with increased concentrations  
of DOTAP (0μM, 3μM, 5μM, 8μM and 10μM) 
 
 
 
 
 
 
 
 
 
 
 
Figure 11: Cell viability of WSU cells treated with increased concentrations of  
1/10 dilution of DOTAP (0μM, 3μM, 5μM 8μM and 10μM) 
 
 
 
 
 
 
 
 
 
 
Figure 12: Cell viability of WSU cells incubated with increased concentrations of 
 Hrp PD-L1 (0μM, 30μM, 50μM and 10μM) and DOTAP as vehicle. 
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c) Effects of PPRHs against PD-L1 with Viromer Green as vehicle 
 
60.000 cells were incubated in 96 well dishes for 48 hours with three different 
hairpins: HrpPD-L1-C WT, HrpBCL-2-C WT and HrpLAC. A negative control with only 
cells and culture, and a positive control with cells, culture and the vehicle (Viromer 
Green) were also included. After analysing the results, a reduction in cell viability was 
observed for treated cells as well as for positive control (Figure 13). This meant that 
cells were not being well transfected and Viromer Green was probably killing them. 
Apart from that, there were no significant differences between the transfection with 
the studied hairpins (HrpPD-L1 and HrpBCL-3) and the control hairpin (HrpLAC). This 
confirmed us the fact that the hairpin was not knocking down gene expression (PD-L1 
and BCL-2) in order to kill the cancer cells.  
 
Figure 13: Cell viability of WSU cells incubated with HrpPD-L1,  
HrpBCL-2 and HrpLAC using Viromer Green as vehicle. 
 
d) Effects of naked PPRHs against PD-L1 
 
20.000 and 30.000 cells were incubated during 72 hours with increased concentrations 
(1μM, 3μM and 5μM) of HrpPD-L1-C WT and HrpLAC without vehicle. Much more 
hairpin concentration was needed because any delivery system was used. In these 
conditions we observed that the treated cells presented the same cell viability than the 
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controls. This was due to the inability of the naked hairpins to get inside the cells so 
they could not silence the genes.  
 
e) Determination of PPRHs internalization by flow cytometry 
 
500.000 cells were incubated during 24h in a final volume of 1mL with increasing 
amounts of a Fluorescent Hairpin (50nM, 100nM or 150nM) and a vehicle: DOTAP 
(5μM or 10μM) or ViromerGreen (1μL, 2μL or 3μL). After 24h incubation the efficacy of 
hairpin delivery was evaluated by cytometry at the Parc Científic of Barcelona (Annex 
III).  
Figure 14: % of WSU cells with fluorescence in relation to the total living WSU cells incubated with a Fluorescent 
Hairpin (DHFR) using DOTAP or Viromer Green as vehicle. 
 
 
Figure 15: Mean fluorescence per WSU cell incubated with a Fluorescent Hairpin (DHFR) using DOTAP or Viromer 
Green as vehicle. 
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The samples treated with 100 nM PPRH with 10μM DOTAP and 50nM PPRH with 1μL 
Viromer were the ones with higher values of fluorescence in relation to total living 
cells (Figure 14). However, the transfection with 1μL of Viromer green showed the best 
results in relation to the mean fluorescence per cell (Figure 15). This meant that 
Viromer green transfected WSU cells better than DOTAP. 
 
Despite the fact that Viromer Green was a better agent for transfection, it was 
extremely toxic for WSU cells. For this reason DOTAP was chosen for the following 
experiments even though it was not the best vehicle. 
 
 
f) Effects of Bendamustine 
 
40.000 and 30.000 WSU cells were incubated with Bendamustine during 48h and 72h 
respectively. Bendamustine is an alkylating agent currently used as a single agent or in 
combination with other anti-cancer agents for indolent non-Hodgkin lymphoma’s 
treatment (29). It was observed that Bendamustine killed lymphoma cells in both 
assays and its effect was dose dependent. 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 16: Cell viability of WSU cells treated with increased concentrations  
of Bendamustine (0, 10, 25, 50, 75, 100, 150, 200 μM) 
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Figure 17: Cell viability of WSU cells treated with increased concentrations  
of Bendamustine (0, 10, 25, 50, 75, 100, 150, 200 μM) 
 
 
g) Effects of the combination of Bendamustine with naked PPRHs against PD-L1  
 
20.000 cells were incubated for 72h and 30.000 cells for 96 hours with Bendamustine 
and naked PPRHs. The experiment was carried out with three different Bendamustine 
concentrations (10μM, 20μM and 30μM). For each concentration we performed a 
negative control, a positive control and three incubations with 1μM, 2μM and 3μM of 
Hairpin.  
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Figure 18, 19, 20: Cell viability of WSU cells treated with  
Bendamustine (10μM, 20μM and 30μM) and naked HrpPD-L1. 
 
 
As shown in the results above (Figure 18, 19, 20), there was no significant difference in 
cell viability between cells treated with Bendamustine and cells treated with 
Bendamustine and the Hairpin. PPRHs transfection without vehicle was not effective. 
 
 
7.2  PD-L1 levels  
 
 
Cell lines Ct specific Ct endogenous _Ct __Ct 2^(-__Ct) % 
PC3 30,56 24,35 6,21 0 1,00 100,00 
PC3 30,59 24,01 6,58 0,37 0,77 77,38 
M2 32,62 23,82 8,8 2,59 0,17 16,61 
M2 32,84 24,21 8,63 2,42 0,19 18,69 
WSU 37,31 24,52 12,79 6,58 0,01 1,05 
WSU 36,45 24,33 12,12 5,91 0,02 1,66 
 
Table 3: Real Time PCR values of the amount of PD-L1 gene  
in PC3, M2 and WSU cell lines.  
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Figure 21: PD-L1 levels in PC3, M2 and WSU cell lines.  
 
PC3 cell line was taken as reference, that’s why its PD-L1 values represent the 100%. 
The results of the RT-PCR analyses reported that PC3 cell line overexpress PD-L1 more 
than MiaPaca-2 or WSU (Figure 21). PD-L1 levels in WSU cells were almost negligible. 
 
7.3 Discussion 
 
As we have seen, non-Hodgkin lymphomas are a type of cancer with high prevalence 
and with a high mortality rate in Spain. That’s why every day, the research of new 
therapeutic alternatives to treat NHL, keeps going. Until now, chemotherapy (CHOP) 
combined with Rituximab (R-CHOP) has considerably increased the survival rate of 
these patients.  However, there are lots of therapeutic possibilities under research that 
could improve even more the regression of lymphomas. Thanks to the current 
knowledge of tumour’s molecular biology, lymphomas subtypes are accurately 
classified today. Thus a better treatment adaptation based on each lymphoma type, its 
aggressiveness and stage can be designed. Furthermore, this progress has lead to the 
development of new-targeted therapies that could complement or strengthen 
chemotherapy regimens. Targeted therapies such as monoclonal antibodies or gene 
therapy produce less systemic effects and reduce the tumour progression. 
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Nowadays Biotechnology and Bioinformatics are promoting the development of 
personalized treatments for cancer patients. Using an adapted medication regimen for 
each tumour we can optimize the lymphoma treatments. Thus, a good tumour 
diagnosis and classification is the key to decide which one of the targeted or classical 
treatments best fits each tumour.  
 
Cancer immunotherapy can be a very good therapeutic alternative to be combined 
with chemotherapy and targeted therapies. Differently from other anti cancer 
therapies, immunotherapy is based on providing to our body the necessary tools to 
fight against the tumour. With this, our immune system can get adapted to the tumour 
changes and destroy all the tumour-spread cells as if they were a foreign antigen. The 
potential is very promising. Could one imagine a better treatment option than 
stimulating the patient’s immune system to fight itself against cancer? 
 
Immunotherapy opens therefore, a new great opportunity for cancer treatment. It is 
currently showing good results for solid tumours, whether it could also be a solution 
for lymphomas and leukaemia still remains unknown. Theoretically, it should be a 
good option for lymphomas as they are always widely scattered and they affect to the 
immune system itself.  
 
Our results show that PPRHs application for WSU cells was quite difficult to carry out. 
WSU cells are very sensitive and really difficult to transfect. As these cells were really 
difficult to transfect, we couldn’t quantify PPRHs transfection against PD-L1 effect for 
WSU. Therefore, we don’t know if PPRHs against PD-L1 would have been effective for 
these cells. The first problem was that none of the tested vehicles were useful for 
these cells, as they resulted to be too cytotoxic. It would be interesting to consider the 
use of other delivery methods such as nanoparticles, biopolymers as alginate or 
protamine or electroporation. As far as I’m concerned, with the appropriate vehicle 
these cells could have been well transfected and PD-L1 could have been silenced. It is 
already proved that PPRHs work well in other cell lines such as breast cancer or 
pancreas cancer. That’s why I strongly believe that this therapy for lymphomas could 
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have worked and it would have reduced cell viability in combination with 
Bendamustine. Unfortunately this cell line had this extra complication.  
 
Apart from that, PD-L1 levels in WSU cells were almost negligible. This meant that 
targeting PD-L1 in this cell line was difficult to perform. PD-L1 is probably not the best 
target option in this type of cells. However, the fact that there is little PD-L1 does not 
have to be negative because it would be easier to reduce their levels to zero. 
 
We have studied all the effects for WSU cells but we could not generalize to all the 
lymphoma types because as we have seen PD-L1 expression can vary a lot from one 
type to another. I consider that PD-L1 levels should be quantified before deciding the 
therapeutic strategy. 
 
Under my point of view decreasing PD-L1 expression with PPRHs of a lymphoma would 
avoid the immune system evasion by the tumours. If we avoid the overexpression of 
PD-L1 from the beginning in lymphomas, our immune system would be able to 
recognise and kill them. This would obviously be a way of enhancing our immune 
system as with the monoclonal antibodies.  
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8 Conclusions 
 
 
- Cancer immunotherapy opens a great opportunity for cancer treatment by 
stimulating the immune system to fight itself against tumour cells. 
 
- PD-L1 is a potential target in cancer research. Preventing PD-L1 from binding to 
its receptors may prevent T-cell suppression. 
 
- Gene therapy allows for an incredible diversity of cancer treatment options 
according to the patient and the type of tumour. 
 
- The combination of targeted therapies such as immunotherapy or gene therapy 
with chemotherapy would improve lymphoma’s patients survival rate. 
 
- Transfection of Polypurine Revers Hoogsteen Hairpins against PD-L1 with the 
liposomes DOTAP or Viromer Green was too toxic for WSU cells. That’s why 
another delivery method such as nanoparticles or biopolymers needs to be 
tested. 
 
- Gene silencing with PPRHs seems to be an in vitro great approach to reproduce 
cancer immunotherapy with monoclonal antibodies. Avoiding PD-L1 
overexpression from the start would reduce the cancer’s immune system 
evasion. 
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10  Annex  
Annex I 
THE REVISED EUROPEAN AMERICAN LYMPHOMA CLASSIFICATION (REAL) 
a) Non-Hodgkin Lymphoma 
- Precursor B-cell neoplasm: 
 Precursor B-lymphoblastic leukemia/lymphoma 
- Mature (peripheral) B-cell neoplasms 
 B-cell chronic lymphocytic leukemia / small lymphocytic lymphoma 
 B-cell prolymphocytic leukemia 
 Lymphoplasmacytic lymphoma 
 Splenic marginal zone B-cell lymphoma (+/- villous lymphocytes) 
 Hairy cell leuekmia 
 Plasma cell myeloma/plasmacytoma 
 Extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid 
tissue type 
 Nodal marginal zone lymphoma (+/- monocytoid B-cells) 
 Follicle center lymphoma, follicular, 
 Mantle cell lymphoma 
 Diffuse large cell B-cell lymphoma 
o Mediastinal large B-cell lymphoma 
o Primary effusion lymphoma 
 Burkitt's lymphoma/Burkitt's cell leukemia 
- Precursor T cell neoplasm: 
 Precursor T-lymphoblastic lymphoma/leukemia 
- Mature (peripheral) T cell and NK-cell neoplasms 
 T cell prolymphocytic leukemia 
 T-cell granular lymphocytic leukemia 
 Aggressive NK-Cell leukemia 
 Adult T cell lymphoma/leukemia (HTLV1+) 
 Extranodal NK/T-cell lymphoma, nasal type 
 Enteropathy-type T-cell lymphoma 
 Hepatosplenic gamma-delta T-cell lymphoma 
 Subcutaneous panniculitis-like T-cell lymphoma 
 Mycosis fungoides/Sézary's syndrome 
 Anaplastic large cell lymphoma, T/null cell, primary cutaneous type 
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 Peripheral T cell lymphoma, not otherwise characterized 
 Angioimmunoblastic T cell lymphoma 
 Anaplastic large cell lymphoma, T/null cell, primary systemic type 
 
b) Hodgkin lymphoma  
 Nodular lymphocyte predominance Hodgkin's lymphoma 
 Classical Hodgkin's lymphoma 
o Nodular sclerosis Hodgkin's lymphoma 
o Lymphocyte-rich classical Hodgkin's lymphoma 
o Mixed cellularity Hodgkin's lymphoma 
o Lymphocyte depletion Hodgkin's lymphoma 
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Annex II 
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Annex III 
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